Eli Lilly Q2: Dividends Don’t Lie
Summary: Eli Lilly and Company reported a superb Q2, triggering a sharp price rally and
Summary: Eli Lilly and Company reported a superb Q2, triggering a sharp price rally and
Summary: Eli Lilly and Company reported Q2 results exceeding expectations and raised 2023 revenue guidance.
Summary: Eli Lilly and Company’s Q2 2023 earnings were boosted by strong sales growth of
Summary: Pharmaceutical company Eli Lilly and Company is purchasing biotech firm Sigilon Therapeutics, Inc. for
Summary: Mounjaro may rake in $25B of annualized sales by 2026, exceeding ABBV’s Humira. This
Summary: Biogen, Eisai, and Eli Lilly’s Alzheimer’s drugs have shown little efficacy, particularly in non-APOE4
Summary: Eli Lilly and Company’s share price won’t stop climbing on the promise of its
Summary: The clinical trial was able to demonstrate a slowing of disease progression, but it’s
Summary: Alzheimer’s drug is expected to receive full approval. Mounjaro formulary placement may fuel sales
Summary: Eli Lilly has seen a massive ramp-up in its diabetes, or better said weight